New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy
August 27, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce...
Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
August 23, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid...
Nuwellis, Inc. Announces Second Quarter 2024 Financial Results
August 13, 2024 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial...
Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions
August 08, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload (the “Company”), today...
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
July 26, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today...
Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules
July 24, 2024 08:02 ET
|
Nuwellis, Inc.
MINNEAPOLIS, July 24, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid...
Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
July 23, 2024 16:10 ET
|
Nuwellis, Inc.
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it...
Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s
July 17, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, July 17, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, is proud to...
New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference
July 09, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, July 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is...
Nuwellis Announces Reverse Stock Split
June 26, 2024 08:45 ET
|
Nuwellis, Inc.
MINNEAPOLIS, June 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid...